IGI INC
NT 10-K, 1999-04-01
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: MEDICAL GRAPHICS CORP /MN/, NT 10-K, 1999-04-01
Next: INSITUFORM TECHNOLOGIES INC, PRE 14A, 1999-04-01





                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12b-25
                           NOTIFICATION OF LATE FILING

[X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR

For the Period Ended:  December 31, 1998

[ ]  Transition  Report  on Form  10-K 
[ ]  Transition  Report  on Form 20-F 
[ ]  Transition Report on Form 11-K 
[ ]  Transition Report on Form 10-Q 
[ ]  Transition Report on Form N-SAR 
For the Transition Period Ended:

If the notification relates to a portion of the filing check above, identify the
Item(s) to which the notification relates:

I.   Registrant Information

     IGI, INC.
     Wheat Road and Lincoln Avenue
     Buena, NJ 08310 - 0687

II.  Rules 12b-25(b) and (c)

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed.

(Check box if appropriate).

[X] (a) The  reasons  described  in  reasonable  detail in Part III of this form
could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, transition report on Form
10-K, Form 20-F, Form 11-K or Form N-SAR, or portion thereof will be filed on or
before the  fifteenth  calendar day following  the  prescribed  due date; or the
subject  quarterly report or transition  report on Form 10-Q, or portion thereof
will be filed on or before the fifth  calendar day following the  prescribed due
date; and

[_] (c) The  accountant's  statement of other exhibit required by Rule 12b-25(c)
has been attached if applicable.


<PAGE>


III. Narrative

State below in reasonable  detail the reasons why Forms 10-K,  20-F, 11-K, 10-Q,
N-SAR or the transition  report or portion thereof could not be filed within the
prescribed time period.

The company requires the extension due to the effect upon its preparation of the
annual 10-K filing  occasioned by the recent  settlement  of regulatory  matters
with the United  States  Departments  of  Agriculture,  Treasury,  and  Justice.
Information  necessary for the proper reporting of the effect of the settlement,
which  was  finalized  on March  23,  could  not be  developed  by the  March 31
filing deadline.

IV.  Other Information

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
notification

           Edward B. Hager, M.D.    (609) 697-1441

(2) Have all other periodic  reports  required under Section 13 or Section 15(d)
of the Securities  Exchange Act of 1934 or Section 30 of the Investment  Company
Act of 1940 during the  preceding 12 months or for such shorter  period that the
registrant was required to file such report(s) been filed?  If the answer is no,
identify report(s)

                                   [X]  Yes      [ ]  No

(3) Is it anticipated  that any significant  change in results of operation from
the  corresponding  period for the last  fiscal  year will be  reflected  by the
earning statements to be included in the subject report or portion thereof?

                                   [_]  Yes      [X]  No

If so, attach an explanation of the  anticipated  change,  both  narratively and
quantitatively,  and if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

                                    IGI, INC.

has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.


<PAGE>


Date: March 31, 1999                            By: /s/ Edward B. Hager, M.D.
                                                  ------------------------------
                                                       Edward B. Hager, M.D.
                                                       Chairman and Chief
                                                       Executive Officer




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission